therapten.com

TheraPten Biosciences Inc.

Restoring functional PTEN tumor suppressor to stop cancer

Restoring functional PTEN to stop cancer

PR61 is designed to put functional PTEN back inside cancer cells — restoring a natural anti-cancer defense frequently lost across human tumors.

The Mechanism: Direct Cellular Defense

The therapy is designed to enter cancer cells directly and reset the body’s anti-cancer defense.

The Delivery: mRNA-LNP Platform

Clinical-trial-ready injectable therapy delivered using mRNA encapsulated in a lipid nanoparticle.

The Clinical Problem: PTEN Deficiency

50–80% of cancer patients ultimately lose functional PTEN, regardless of tumor type or stage.

"Trojan Horse" Delivery

PR61 is TheraPten’s patented, “Trojan horse”-like PTEN technology.

PR61 mRNA → lipid nanoparticle → intravenous injection protein expression by the liver → functional PTEN expression

Patholab Provides the best laboratory experience

A cell-permeable PTEN approach designed to restore a naturally occurring tumor-suppressor pathway.

PTEN Biology PR61 Profile PR61 Mechanism Delivery and potential impact Core invention

✓
PTEN is a natural human protein that suppresses tumors and promotes longevity.
✓
Loss of PTEN inside the cancer cell is one of the first events in cancer development.
✓
PTEN is missing or dysfunctional in 50–80% of human tumors across tumor type and stage.
✓
PTEN was identified in 1997 by Prof. Ramon Parsons at Columbia University; Prof. Parsons and Columbia University are TheraPten shareholders.

✓
Manufacturable to industrial standards
✓
Not toxic in preclinical studies
✓
Secreted from the human liver in large amounts
✓
Targets cancer cells
✓
Enters cancer cells directly to reset the body’s anti-cancer defense — the “Trojan horse” concept

✓
Approximately only 1% of roughly 35,000 natural and man-made proteins can enter cells directly.
✓
TheraPten has generated and patented PR61, a cell-permeable form of PTEN.

✓
PR61 is delivered by standard intravenous injection of PR61 mRNA encapsulated in a lipid nanoparticle, using the same broad delivery principle as mRNA vaccines.
✓
In animal studies, up to 100% of mice responded with significant tumor reduction and no toxicity.
✓
Up to 2 million cancer patients each year in the Western world alone could potentially benefit from treatment.

✓
Issued U.S. patent covering the PR61 albumin‑PTEN minigene; patent applications pending in the EU and China.

Initial oncology focus, with longevity as the next frontier of PTEN biology.

PR61 development pipeline

PR61 will initially be developed for two orphan cancer indications and one major cancer indication relevant to PTEN Hamartoma Tumor Syndrome (PHTS). PHTS patients are born with approximately 50% less PTEN and develop cancers with high propensity throughout life.

Program	Indication focus	Rationale	Current positioning
PR61 Oncology	2 orphan cancer indications	High-need settings where PTEN biology is central	Initial development focus
PR61 Oncology	1 major cancer indication	Broader PTEN-deficient cancer opportunity	Expansion indication
PHTS-related cancers	PTEN Hamartoma Tumor Syndrome	Patients are born with ~50% less PTEN and have elevated lifetime cancer risk	Biology-driven rationale
PR61 Longevity	Healthy aging / longevity biology	PTEN overexpression studies show cancer resistance, cardiometabolic fitness benefits and 16% longer life expectancy vs controls	Next frontier / preclinical evidence

PTEN replacement platform: Oncology first, then broader PTEN biology

TheraPten has obtained preclinical evidence that PR61 recapitulates at least one longevity aspect of PTEN.

The Expertise Behind TheraPten

Leadership & Advisors

Deep oncology, drug development, capital markets, and regulatory experience

Nassos Alevizopoulos, PhD, MBA

CEO & Chairman

30+ years in translational science and drug development across small biotechs and multinationals including Novartis. Led oncology biologics and liposomal therapeutics; strong CMC and IND drafting experience with four biologics placed in the clinic. PhD in Molecular Biology, Lausanne University; MBA, Lausanne University.

Harvey Lalach

CBO & Director

25+ years of project management and business development across start-ups, small-cap public companies, capital markets and securities regulation. Focused on biotech for 15+ years; co-founder of TheraPten and former co-founder / President of a CNS and oncology drug discovery company.

Prof. Ramon Parsons, MD, PhD

Co-founder & Scientific Advisor

Chair of Oncological Sciences, Icahn School of Medicine at Mount Sinai. Discovered PTEN in 1997; major contributor to the PI3K/PTEN pathway, PTEN cancer mouse models and PTEN biology. Former Professor at Columbia University.

Maximilien Murone, PhD, MBA

Co-founder & Business Advisor

27+ years in life sciences, oncology and drug development. Board member of Avrion Therapeutics and former CEO; prior VP Operations & Strategy at Affivant, COO at Cellestia Biotech and Associate Director at Debiopharm. PhD, ISREC, Lausanne; executive MBA, HEC Lausanne; postdoctoral research at Genentech.

George Paganis, MBA

Director

50+ years of business experience. Founder and former owner of a successful medical device company in Greece; active business leader and early TheraPten investor. BA Economics, Ripon College; MBA, JFK University

TeraPten Biosciences Inc.

101-1865 Dilworth Dr, #705
Kelowna, BC V1Y 9T1
Canada

reachout@therapten.com

reachout@therapten.com